Start the process right – for ADC drug development success

Selecting the right target for your antibody drug conjugate as part of early drug development is key to success further down the line for all pharmaceutical companies developing an ADC.

As part of the World ADC Series, the inaugural ADC Target Selection Summit is the go-to for scientists involved within target selection, cancer biology and bioinformatics as thought leaders within the field discuss strategies for successful ADC target selection, understanding methods for choosing the target-payload pairing and defining the criteria of what makes a good target for antibody drug conjugates.

Join 80+ of your peers including AstraZeneca, Daiichi Sankyo, CytomX and other leading organisations dedicated to target selection and validation as they share their rationale for target selection, the latest scientific progress and how to overcome key challenges early on to develop more life-changing ADCs for patients of highly unmet needs.

World-Class Speaker Faculty

Bill Mallet

Staff Scientist

Target Validation Bolt Bio

Christoffer Nielson

COO & Co-founder

Adcendo

Elaine Hurt

Director, Bioscience

AstraZeneca

Hans Peter Gerber

Chief Scientific Officer

3T Bioscionces

Regina Reilly

Oncology Discovery, Biologics & Research Fellow

AbbVie